文献速递认知障碍与痴呆

无症状阿尔茨海默病:定义韧性

Asymptomatic Alzheimer disease: Defining resilience.
PubMed 文献 · Neurology · 2016-11-04

研究利用阿尔茨海默病脑脊液生物标志物,在潜变量框架下定义韧性指标,并在认知正常(n=297)和轻度认知障碍(n=432)人群中验证其预测认知下降和诊断转换的能力。结果显示韧性潜变量可预测诊断转换风险降低、认知下降减慢和脑室扩张速率减慢,且在生物标志物阳性且低韧性个体中下降风险最高。

要点

  • 韧性指标通过脑脊液生物标志物与脑老化结局回归残差定义,正残差表示高韧性。
  • 韧性潜变量预测诊断转换风险降低(HR<0.54)、认知下降减慢(β>0.02)和脑室扩张减慢(β<-4.7)。
  • 生物标志物阳性且低韧性个体后续下降风险最高。

核心结论

  • 基于AD生物标志物和基线脑老化结局计算的韧性表型可识别短期下降风险最高的个体。

研究设计与样本

  • 研究从阿尔茨海默病神经影像学倡议中纳入认知正常者297例和轻度认知障碍者432例。
  • 基线时通过回归脑老化结局(海马体积和认知)对脑脊液生物标志物得到残差来定义韧性指标。
  • 将残差整合入韧性潜变量模型,并验证其独立预测诊断转换、认知下降和脑室扩张速率的能力。

主要发现

  • 韧性潜变量预测诊断转换风险降低(风险比<0.54,p<0.0001)。
  • 韧性潜变量预测认知下降更慢(β>0.02,p<0.001)。
  • 韧性潜变量预测脑室扩张速率更慢(β<-4.7,p<2×10^-15)。
  • 上述结果在仅分析临床正常个体时仍显著。
  • 韧性指标与生物标志物状态存在交互作用,生物标志物阳性且低韧性个体后续下降风险最高。

临床怎么用

  • 利用脑脊液生物标志物和基线脑老化结局计算的韧性指标有助于识别短期认知下降风险高的个体,尤其是生物标志物阳性者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To define robust resilience metrics by leveraging CSF biomarkers of Alzheimer disease (AD) pathology within a latent variable framework and to demonstrate the ability of such metrics to predict slower rates of cognitive decline and protection against diagnostic conversion. METHODS: Participants with normal cognition (n = 297) and mild cognitive impairment (n = 432) were drawn from the Alzheimer's Disease Neuroimaging Initiative. Resilience metrics were defined at baseline by examining the residuals when regressing brain aging outcomes (hippocampal volume and cognition) on CSF biomarkers. A positive residual reflected better outcomes than expected for a given level of pathology (high resilience). Residuals were integrated into a latent variable model of resilience and validated by testing their ability to independently predict diagnostic conversion, cognitive decline, and the rate of ventricular dilation. RESULTS: Latent variables of resilience predicted a decreased risk of conversion (hazard ratio < 0.54, p < 0.0001), slower cognitive decline (β > 0.02, p < 0.001), and slower rates of ventricular dilation (β < -4.7, p < 2 × 10-15). These results were significant even when analyses were restricted to clinically normal individuals. Furthermore, resilience metrics interacted with biomarker status such that biomarker-positive individuals with low resilience showed the greatest risk of subsequent decline. CONCLUSIONS: Robust phenotypes of resilience calculated by leveraging AD biomarkers and baseline brain aging outcomes provide insight into which individuals are at greatest risk of short-term decline. Such comprehensive definitions of resilience are needed to further our understanding of the mechanisms that protect individuals from the clinical manifestation of AD dementia, especially among biomarker-positive individuals.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Hohman TJ, McLaren DG, Mormino EC, et al. Asymptomatic Alzheimer disease: Defining resilience. Neurology. 2016. PMID: 27815399

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。